TrialCancer research communications2024

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.